# Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19

> **NCT05268939** · NA · COMPLETED · sponsor: **LumiraDx UK Limited** · enrollment: 668 (actual)

## Conditions studied

- COVID-19
- Influenza A
- Influenza Type B
- RSV Infection

## Interventions

- **DIAGNOSTIC_TEST:** LumiraDx SARS-CoV-2 & Flu A/B test
- **DIAGNOSTIC_TEST:** LumiraDx SARS-CoV-2 & RSV test

## Key facts

- **NCT ID:** NCT05268939
- **Lead sponsor:** LumiraDx UK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-04
- **Primary completion:** 2022-04-25
- **Final completion:** 2023-03-14
- **Target enrollment:** 668 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268939, "Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT05268939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*